Wegovy 3-Month Supply: What the Evidence Says About Those First Twelve Weeks

Where the clinical evidence starts: what months one to three are for

The STEP 1 trial, which followed 1,961 adults over 68 weeks, showed an average weight reduction of around 15% at the 2.4mg maintenance dose. That figure is the headline, but the path to it matters. Participants spent the first sixteen weeks or so working through the lower doses before reaching 1.7mg and then 2.4mg. The early part of treatment is not where most of the weight loss happens; it is where the groundwork is laid.

Months one to three sit almost entirely within that groundwork phase. Doses of 0.25mg, 0.5mg and 1.0mg are, by design, below the therapeutic maintenance level. The body is adjusting to the medicine, and the prescriber is watching how you respond. Some people notice reduced appetite and modest weight change during these weeks. Others find the effect more gradual. Both experiences are consistent with what the trial data showed.

The NHS medicines page for semaglutide describes this titration approach clearly: starting low reduces the likelihood of gastrointestinal side effects, which are the most commonly reported reason people find the first few weeks uncomfortable. Nausea, indigestion, loose stools and fatigue are most likely to appear when a dose changes, then typically settle within a week or two. Knowing this in advance tends to make those early weeks easier to manage.

How a 3-month Wegovy bundle fits the licensed schedule

Wegovy's UK titration runs through five steps: 0.25mg, 0.5mg, 1.0mg, 1.7mg and 2.4mg. A three-month supply, covering months one through three, spans the first three of those, and our Wegovy bundle is structured around exactly this schedule, with each pen delivering four weekly injections at its set dose so that three pens gives you twelve weeks of treatment, one per step in the schedule.

It is worth being clear about what this means practically. By the end of month three you will typically be at 1.0mg, which is still below the standard maintenance dose. Some patients titrate more slowly if side effects are present; others may be ready to move to 1.7mg on schedule. That decision sits with the prescriber, not a fixed calendar.

If you want to understand how months two and three compare in terms of what each dose typically involves, month two of Wegovy and month three are covered in their own pages. The practical information on what arrives and what to expect at each step may be useful alongside this overview.

One detail worth noting: when a pen arrives via DPD in plain, unbranded packaging, it needs to go straight into the fridge. Wegovy pens are stored at 2 to 8°C; the Patient Information Leaflet gives the exact window for room-temperature use if you need it when you are away from home.

Side effects in the first three months: what the data shows

Gastrointestinal effects are the most frequently reported side effects with semaglutide. In the STEP 1 trial, nausea was reported by a substantial proportion of participants, particularly in the titration phase. The pattern is consistent: effects are most noticeable in the 24 to 72 hours after a dose, especially after a step up, and tend to diminish as the weeks pass.

Common experiences include nausea, vomiting, constipation, diarrhoea, reflux and general fatigue. Headaches and dizziness are also reported. None of this means side effects are inevitable, but it is honest to say that the first three months are often when they are most present.

There are some symptoms that require prompt medical attention. Severe or persistent stomach pain that spreads to the back, with or without vomiting, can be a sign of pancreatitis, an infrequent but serious side effect. The MHRA highlighted this in a Drug Safety Update in January 2026 for GLP-1 medicines. If you experience this, stop the injection and get medical help rather than waiting for your next review.

Patients can report side effects, including unexpected or serious ones, through the Yellow Card scheme. At nume, our clinical team is available seven days a week if something concerns you between doses.

After the first three months: where treatment goes next

The first three months are the beginning, not the treatment itself in full. Most people reach the maintenance dose of 2.4mg somewhere between months four and five, depending on how the titration goes. The evidence for weight loss accumulates over the full course, and stopping early, particularly in the titration phase, means stopping before the medicine has had the chance to work at its intended level.

For context on what month four typically involves, the month four page covers the move toward or onto the maintenance dose. The broader picture of how semaglutide works as a medicine is also worth reading if you want to understand the mechanism behind the titration schedule rather than just the steps themselves.

On cost: private Wegovy treatment is priced per pen, and a three-month bundle is one way providers structure supply. If you want to compare how providers price this, our Wegovy price comparison sets out what to look for beyond the headline figure, including what should be included in any legitimate private prescription service. At nume, one price covers the clinical consultation, prescription, and free next-working-day tracked delivery. There are no subscriptions and no auto-renewals; each repeat is reviewed before it goes out.

If you are thinking about starting, speaking to a prescriber is the right first step. Speak to our prescribers through a free consultation and find out whether Wegovy is clinically suitable for you.